Nanomedicine · 2020 · 12 citations · 13 references
MedicineOncologyPharmacologyCancer ImmunologyChemotherapyMetastasisBreast Cancer PharmacotherapyCancer ImmunotherapyCombination ChemotherapyMetastatic Breast CancerMetastatic Disease TreatmentTumor Microenvironment ModulationAnticancer ChemotherapyAntitumor Immune ActivationBreast Cancer ChemotherapyChemotherapy DeliveryChemotherapy-induced Immunogenic Cell DeathImmunogenic Cell Death InductionMetastatic Breast Cancer TreatmentMetastatic Mechanisms
Aim: To investigate the effect of liposomes containing the classical cytotoxic drugs paclitaxel and doxorubicin (Lipo-Pacli/Dox), against a metastatic breast cancer model. We also investigated if Lipo-Pacli/Dox was capable of reverting the tolerogenic environment of metastatic lesions. Materials & methods: Immunogenic cell death induction by the Pacli/Dox combination was assessed in vitro. Antitumor activity and in vivo safety of Lipo-Pacli/Dox were evaluated using a 4T1 breast cancer mouse model Results: Lipo-Pacli/Dox, with a size of 189 nm and zeta potential of -5.01 mV, promoted immune system activation and partially controlled the progression of pulmonary metastasis. Conclusion: Lipo-Pacli/Dox was useful to control both primary tumor and lung metastasis in breast cancer (4T1) mice model. Additionally, Lipo-Pacli/Dox acts as an immunological modulator for this metastatic breast cancer model.
13
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obéid, Antoine Tesnière, François Ghiringhelli et al. · Nature Medicine · 2006 · 3.1K citations
Medicine, Immunology, Oncology +14
Model Predicting Survival in Stage I Melanoma Based on Tumor Progression
W. H. Clark, David E. Elder, DuPont Guerry et al. · JNCI Journal of the National Cancer Institute · 1989 · 1.2K citations
Medicine, Dermatology, Oncology +17